SilverJ.Molecular mechanisms of secondary hyperparathyroidism.Nephrol Dial Transplant2000; 15(Suppl 5): S2–7.
2.
SlatopolskyE., BrownA., DussoA.Pathogenesis of secondary hyperparathyroidism.Kidney Int1999; 56(Suppl 73): S14–9.
3.
BroS., OlgaardK.Effects of excess PTH on nonclassical target organs.Am J Kidney Dis1997; 30: 606–20.
4.
BrownE.M., GambaG., RiccardiD.. Cloning and Charaterization of an extracellular Ca2-sensing receptor from bovine parathyroid.Nature1993; 366: 575–80.
5.
BlacherJ., GuerinA.P., PannierB., MarchaisS.J., LondonG.M.Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal.Hypertension2001; 38: 938–42.
6.
SlagueiraM.Vascular calcification in the uremic patient: a cardiovascular risk?Kidney Int2003; 63(suppl): S119–21.
7.
WangA.Y., WangM., WooJ.. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study.J Am Soc Nephrol2003; 14: 159–68.
8.
ParfittA.M.The hyperparathyroidism of chronic renal failure: a disorder of growth.Kidney Int1997; 52: 3–9.
9.
CozzolinoM., ButtiA., ChiarelliG.. New insights in the pathogenesis of secondary hyperparathyroidism.G Ital Nefrol2005; 4: 329–36.
SilverJ., Bar SelaS., and Naveh-ManyT.Regulation of parathyroid cell proliferation.Curr Opin Nephrol Hypertens1997; 6: 321–26.
12.
CozzolinoM., BrancaccioD., GallieniM.. Pathogenesis of parathyroid hyperplasia in renal failure.J Nephrol2005, 18(1Il calciomimetico nell'iperparatiroidismo primitivo e se): 5–8.
13.
CozzolinoM., DussoA., SlatopolskyE.Role of calcium x phosphate product and bone associated proteins on vascular calcification in renal failure.J Am Soc Nephrol2001; 12: 2511–6.
14.
CozzolinoM., BrancaccioD., GallieniM., SlatopolskyE.Pathogenesis of vascular calcification in chronic kidney disease.Kidney Int2005; 68: 429–36.
15.
CozzolinoM., GallieniM., BrancaccioD.. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.J Nephrol2006; 19: 566–57.
16.
LevinA., AndressL.D., MolitchM.. Prevalence of abnormal PTH in relation to serum calcium, phosphorus and vitamin D in patients with stage 3 and 4 Chronic Kidney Disease (CKD).JASN2005 (Abstract Meeting ASN 2005).
17.
KawashimaH., KrautJ.A., KurokawaK.Metabolic acidosis suppresses 25-hydroxyvitamin D3–1alpha-hydroxylase in the rat kidney.J Clin Invest1982; 70: 135–40.
18.
Nesby-O'DellS., ScanlonK.S., CogswellM.E.. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988–1994.Am J Clin Nutr2002; 76: 187–92.
19.
GallieniM., KamimuraS., AhmedA.. Kinetics of monocyte 1α-hydroxylase in renal failure.Am J Physiol1995; 268: F746–53.
20.
LiuW., YuW.R., CarlingT.. Regulation of gp330/megalin expression by vitamins A and D.Eur J Clin Invest1998; 28: 100–07.
21.
RaggiP., BoulayA., Chasin-TaberS.. Cardiac calcification in adult hemodialysis patients.A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol2002; 39: 695–701.
22.
LondonG.M., GuerinA.P., MarchaisS.J.. Arterial medial calcification in end-stage renal disease: impact on all cause and cardiovascular mortality.Nephrol Dial Transplant2003; 18: 1731–40.
23.
YildizA., MemisogluE., OflazH.. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic hemodialysis patients.Nephrol Dial Transplant2005; 20: 760–7.
24.
GuerinA.P., BlacherJ., PannierB.. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure.Circulation2001; 103: 987–92.
25.
BlacherJ., GuerinA.P., PannierB.. Arterial calcifications, arterial stiffness and cardiovascular risk in endstage renal disease.Hypertension2001; 38: 938–42.
26.
DucyP., ZhangR., GeoffroyV.. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.Cell1997; 89: 747–54.
27.
SjodenG., LindgrenJ.U., DeLucaH.F.Antirachitic activity of 1 alpha-hydroxyergocholecalciferol and 1 alpha-hydroxycholecalciferol in rats.J Nutr1984; 114: 2043–6.
28.
GonzalezE.A., SachdevaA., OliverD.A., MartinK.J.Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study.Am J Nephrol2004; 24: 503–10.
29.
HealyM.D., MallucheH.H., GoldsteinD.A.. Effects of long-term therapy with calcitriol in patients with moderate renal failure.Arch Intern Med1980; 140: 1030–33.
30.
CoburnJ.W., MaungH.M., ElangovanL.. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.Am J Kidney Dis2004; 43: 877–90.
31.
RixM., AndreassenH., EskildsenP.. Bone mineral density and biochemical markers of bone turnover in patients with pre-dialysis chronic renal failure.Kidney Int1999; 56: 1084–93.
32.
National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.Am J Kidney Dis2003; 42(Suppl 3): S1–201.
33.
CaglarK., YilmazM.I., SaglamM.. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.Clin J Am Soc Nephrol2008; 3: 61–8.
34.
SpragueS.M., AbboudH., QiuP.. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.Clin J Am Soc Nephrol.2009; 4: 178–85.
SlatopolskyE., CozzolinoM., FinchJ.L.Differential effects of 19-nor-1,25-(OH)2D2 and 1alpha-hydroxyvitamin D2 on calcium and phosphorum in normal and uremic rats.Kidney Int2002; 62: 1277–84.
37.
TengM., WolfM., OfsthunM.N.. Activated injectable vitamin D and hemodialysis survival: a historical cohort study.J Am Soc Nephrol2005; 16: 1115–25.
KawataT., ImanishiY., KobayashiK.. Relationship between parathyroid calcium sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism.Eur J Endocrinol2005; 153: 587–94.
40.
BlockG., KevinJ.M., De FranciscoA.L.M.. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.N Engl J Med2004; 350: 627–35.
41.
MoeS.M., ChertowG.M., CoburnJ.W.. Achieving NFK-K/DOQI TM bone metabolism and disease treatment goals with cinacalcet HCl.Kidney Int2005; 67: 760–71.
42.
ChoncholM., LocatelliF., AbboudH.E.. A randomized, double-blind, placebo-controlled study to assess the efficacy an safety of cinacalcet HCl in participants with CKD not receiving dialysis.Am J Kidney Dis2008; Dec 23.
